GLPGN Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
GLPGN FAQ
What was Galapagos NV (UK)’s price range in the past 12 months?
Currently, no data Available
What is Galapagos NV (UK)’s market cap?
Galapagos NV (UK)’s market cap is $33.69B.
When is Galapagos NV (UK)’s upcoming earnings report date?
Galapagos NV (UK)’s upcoming earnings report date is Aug 10, 2026 which is in 16 days.
How were Galapagos NV (UK)’s earnings last quarter?
Galapagos NV (UK) released its earnings results on May 06, 2026. The company reported $4.187 earnings per share for the quarter, beating the consensus estimate of -$16.25 by $20.437.
Is Galapagos NV (UK) overvalued?
According to Wall Street analysts Galapagos NV (UK)’s price is currently Undervalued.
Does Galapagos NV (UK) pay dividends?
Galapagos NV (UK) does not currently pay dividends.
What is Galapagos NV (UK)’s EPS estimate?
Galapagos NV (UK)’s EPS estimate is -13.96.
How many shares outstanding does Galapagos NV (UK) have?
Galapagos NV (UK) has 65,897,070 shares outstanding.
What happened to Galapagos NV (UK)’s price movement after its last earnings report?
Galapagos NV (UK) reported an EPS of $4.187 in its last earnings report, beating expectations of -$16.25. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Galapagos NV (UK)?
Currently, no hedge funds are holding shares in MX:GLPGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Galapagos NV (UK)
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.